HCM
CADL icon

Heights Capital Management’s Candel Therapeutics CADL Stock Holding History

Heights Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-775,000
Closed -$3.8M – 324
2026
Q1 		$3.8M Buy
+775,000
New +$4.22M 1.06% 20
2025
Q1 		– Sell
-30,000
Closed -$260K – 132
2024
Q4 		$260K Buy
+30,000
New +$177K 0.13% 55

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Heights Capital Management's CADL Position: Q2 2026 in Review

Heights Capital Management sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 775,000 shares — an estimated $3.8M sold.

Heights Capital Management first reported a position in CADL in Q4 2024 and held it in 2 quarters. The position peaked at $3.8M in Q1 2026. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Heights Capital Management reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Heights Capital Management sold 775,000 Candel Therapeutics shares in Q2 2026, an estimated $3.8M.
  • Heights Capital Management first reported a position in Candel Therapeutics in Q4 2024 and held it in 2 quarters.
  • Heights Capital Management's Candel Therapeutics position peaked at $3.8M in Q1 2026.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.